ABBV 514
Alternative Names: ABBV-514Latest Information Update: 06 Dec 2023
At a glance
- Originator AbbVie
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer; Squamous cell cancer
Most Recent Events
- 01 Nov 2021 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater, Combination therapy) in Japan (IV) (NCT05005403) (EudraCT 2021-002715-65)
- 01 Nov 2021 Phase-I clinical trials in Non-small cell lung cancer (Monotherapy, Second-line therapy or greater, Late-stage disease, Refractory metastatic disease) in Japan (IV) (NCT05005403) (EudraCT 2021-002715-65)
- 01 Nov 2021 Phase-I clinical trials in Squamous cell cancer (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in Japan (IV) (NCT05005403) (EudraCT 2021-002715-65)